Amarin Corp says that it has closed the $30.0 million first tranche of its previously announced $60.0 million private placement. The net proceeds, after deducting the placement agents' fees and estimated offering expenses, will be around $27.0 million.
In conjunction with the financing, Amarin has appointed to its board representatives of the four largest investors in the placement. The new non-executive directors are James Healy of Sofinnova Ventures, Carl Gordon of OrbiMed Advisors, Eric Aguiar of Thomas, McNerney & Partners and Srinivas Akkaraju of Panorama Capital. Non-executive directors retiring from the Amarin board are John Groom, Simon Kukes, Prem Lachman, William Hall and Michael Walsh.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze